The J9282 code for ZUSDURI facilitates billing and reimbursement, improving patient access to bladder cancer treatment. ZUSDURI, approved by the FDA in June 2025, is the first medication for recurrent ...
In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC. Teoh ...
The Vanquish Water Vapor System and Hugo robotic-assisted surgery system received FDA clearance for prostate cancer and urologic procedures, respectively, demonstrating high effectiveness and safety.
Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI ...
FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...
ADAM, a non-hormonal male contraceptive, shows promise with a favorable safety profile and sustained efficacy in early trials. FDA updates testosterone product labels, removing cardiovascular risk ...
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
Zoliflodacin is approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, effective against drug-resistant strains. A phase 3 trial showed zoliflodacin's non-inferior ...
Maxwell L. Sandberg, MD, highlights recent study findings on the role for perioperative systemic therapy for renal cell carcinoma with a tumor thrombus. Recent findings from a retrospective study ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback